Previous Article | Next Article 
Journal of Virology, April 2001, p. 3613-3625, Vol. 75, No. 8
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.8.3613-3625.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Degradation of p21cip1 in Cells
Productively Infected with Human Cytomegalovirus
Zhenping
Chen,1
Eugene
Knutson,1
Alexander
Kurosky,2 and
Thomas
Albrecht1,*
Departments of Microbiology and
Immunology1 and Human Biological
Chemistry and Genetics,2 The University of
Texas Medical Branch, Galveston, Texas 77555-1019
Received 17 October 2000/Accepted 12 January 2001
 |
ABSTRACT |
Human cytomegalovirus (HCMV) stimulates arrested cells to enter the
cell cycle by activating cyclin-dependent kinases (Cdks), notably Cdk2.
Several mechanisms are involved in the activation of Cdk2. HCMV causes
a substantial increase in the abundance of cyclin E and stimulates
translocation of Cdk2 from the cytoplasm to the nucleus. Further, the
abundance of the Cdk inhibitors (CKIs) p21cip1/waf1
(p21cip1) and p27kip1 is substantially reduced.
The activity of cyclin E/Cdk2 increases as levels of CKIs, particularly
p21cip1, fall. We have previously shown that these
phenomena contribute to priming the cell for efficient replication of
HCMV. In this study, the mechanisms responsible for the decrease in
p21cip1 levels after HCMV infection were investigated by
measuring p21cip1 RNA and protein levels in permissive
human lung (LU) fibroblasts after HCMV infection. Northern blot
analysis revealed that p21cip1 RNA levels increased briefly
at 3 h after HCMV infection and then decreased to their nadir at
24 h; thereafter, RNA levels increased to about 60% of the
preinfection level. Western blot analysis demonstrated that the
relative abundance of p21cip1 protein roughly paralleled
the observed changes in initial RNA levels; however, the final levels
of protein were much lower than preinfection levels. After a transient
increase at 3 h postinfection, p21cip1 abundance
declined sharply over the next 24 h and remained at a very low
level through 96 h postinfection. The disparity between p21cip1 RNA and protein levels suggested that the
degradation of p21cip1 might be affected in HCMV-infected
cells. Treatment of HCMV-infected cells with MG132, an inhibitor of
proteasome-mediated proteolysis, provided substantial protection of
p21cip1 in mock-infected cells, but MG132 was much less
effective in protecting p21cip1 in HCMV-infected cells. The
addition of E64d or Z-Leu-Leu-H, each an inhibitor of calpain activity,
to HCMV-infected cells substantially increased the abundance of
p21cip1 in a concentration-dependent manner. To verify that
p21cip1 was a substrate for calpain, purified recombinant
p21cip1 was incubated with either m-calpain or µ-calpain,
which resulted in rapid proteolysis of p21cip1. E64d
inhibited the proteolysis of p21cip1 catalyzed by either
m-calpain or µ-calpain. Direct measurement of calpain activity in
HCMV-infected LU cells indicated that HCMV infection induced a
substantial and sustained increase in calpain activity, although there
was no change in the abundance of either m- or µ-calpain or the
endogenous calpain inhibitor calpastatin. The observed increase of
calpain activity was consistent with the increases in intracellular
free Ca2+ and phospholipid degradation in HCMV-infected LU
cells reported previously from our laboratory. Considered together,
these results suggest that the increase in calpain activity observed
following HCMV infection contributes significantly to the reduction of
p21cip1 levels and the resultant cell cycle progression.
 |
INTRODUCTION |
Human cytomegalovirus (HCMV)
infection is widespread among human populations, primarily as a
subclinical persistent infection. Furthermore, HCMV infection is a
majsor cause of morbidity and mortality in several well-studied risk
groups. These include congenitally infected infants and individuals
with compromised immune systems, particularly after human
immunodeficiency virus infection or immunosuppressive therapy for
tissue transplantation (for reviews, see references 8, 29, 68,
and 72). The clinical management of these infections is still
problematic. Although several agents with potent antiviral activity for
HCMV infection both in vitro and in vivo have been identified, the
toxicity associated with the long-term use of these drugs makes
clinical management difficult, and drug-resistant strains of HCMV have
emerged (for a review, see reference 61). Thus, there
continues to be great interest in improving our understanding of the
replication of HCMV with a view toward developing more effective
approaches to control these infections.
HCMV replication is associated with extensive modifications of cellular
metabolism (reviewed in references 4 and 5), leading to a
number of physiologic changes and the activation of a large number of
cellular genes (91). Initially, HCMV infection induces a
series of cellular responses that resemble the immediate-early events
observed following activation of serum-arrested cells by serum
growth factors (4). These include hydrolysis of
phosphatidylinositol 4,5-bisphosphate, yielding increased cellular
levels of sn-1,2-diacylglycerol (DG) and inositol
1,4,5-trisphosphate (81); increased release of arachidonic
acid and its metabolites (1, 2); changes in
Ca2+ homeostasis, including Ca2+ influx,
release of Ca2+ stores, and an increase in intracellular
free Ca2+ (58); transcriptional activation of
cellular oncogenes c-fos, c-jun, and
c-myc (11, 12, 13); and increased activity of the DNA-binding proteins NF
B, AP-1, and CREB (14). The
signaling cascade induced by HCMV infection induces a robust mitogenic
response, as evidenced by the ability of HCMV to stimulate cell cycle
entry by density-arrested cells, which are resistant to stimulation by
serum growth factors (19). Recent results indicate that
productive HCMV infection stimulates cell cycle progression in either
serum- or density-arrested cells through late G1 phase to a
point at or near the G1/S boundary (19, 30,
52). Closely associated with this limited traverse of the cell
cycle is an increase in cyclin E/cyclin-dependent kinase 2 (Cdk2)
activity, hereafter referred to as E kinase activity, and
hyperphosphorylation of pRb, releasing E2F (45).
Activation of E2F, together with Myc, leads to an increase in the
cellular levels of a large number of genes involved in nucleotide
biosynthesis which primes the infected cell for DNA synthesis (5,
7).
Three HCMV-induced events appear to be necessary for activation of E
kinase activity: (i) transcriptional activation of cyclin E
(17), (ii) translocation of Cdk2 from the cytoplasm to the nucleus (20), and (iii) a substantial decrease in the
nuclear levels of the cyclin kinase inhibitors (CKIs)
p21cip1/waf1 (hereafter p21cip1) and
p27kip1 (19). Activation of E kinase appears
to be critical for efficient HCMV replication, since drugs that
interfere with the activity of Cdk2 substantially reduce infectious
yields (18). The precise mechanisms through which these
virus-induced cellular modifications are achieved are poorly
understood. Our long-term goal is to better understand the events that
prime the cell for HCMV replication. We are especially interested in
the mechanism of reduction of cellular levels of p21cip1
during HCMV infection, since this event appears to be closely associated with the increase in E kinase activity (19).
p21cip1 is a potent inhibitor of Cdks (41, 42,
84) and is a critical p53-induced downstream effector in the
growth-suppressive pathway (33). p21cip1 binds
cyclin-Cdk complexes, thereby inhibiting the activity of Cdks, such as
Cdk2, Cdk3, Cdk4, and Cdk6, and consequently inhibiting cell cycle
progression. In addition, p21cip1 interacts with
proliferating cell nuclear antigen (36) and gadd45
(48), affecting their function, e.g., interfering with DNA
replication and repair (24, 36, 51, 60, 62, 82, 86).
p21cip1 may also be involved in p53-mediated apoptosis
(39) and in the control of cell senescence
(57).
Despite significant advances in our understanding of how
p21cip1 exerts its biological effects and is
transcriptionally regulated, little is known about how the stability of
p21cip1 is regulated under the physiologic conditions
associated with disease and other forms of stress. Nonlysosomal
cytoplasmic protease systems have been identified as important
regulators of cell cycle progression (26, 28, 35, 59, 70,
71). Two prominent cytoplasmic protease pathways have been
identified: the ubiquitin-proteasome pathway and the calpain pathway.
Many of the cell cycle regulatory proteins that are degraded at
specific points in the cell cycle, e.g., cyclins A, B, and E, are
substrates of the ubiquitin-proteasome pathway. It has also been
reported that p21cip1 is subject to proteolysis by
ubiquitin-mediated proteasome degradation (10, 35, 38,
85). In this study, we undertook a series of experiments to
investigate the proteolytic degradation of p21cip1 in cells
productively infected with HCMV. Consistent with previous work, we
observed that the ubiquitin-proteasome pathway is the predominant
mechanism mediating the proteolysis of p21cip1 in
mock-infected or noninfected human embryonic lung (LU) cells. In
HCMV-infected LU cells, calpain is activated and is the predominant proteolytic mechanism mediating degradation of p21cip1.
HCMV infection induced a substantial and prolonged increase in calpain
activity when measured in intact cells using fluorogenic substrates or
in lysates of infected cells by zymography. The time course for the
HCMV-induced increase in calpain activity was consistent with the
temporal pattern of p21cip1 degradation, and inhibitors of
calpain-mediated proteolysis interfered with p21cip1
degradation, resulting in a substantial increase in its abundance. These findings provide an explanation for the sustained decrease in
p21cip1 abundance observed in HCMV-infected cells and,
accordingly, help to explain the prolonged activation of E kinase in
HCMV infection.
 |
MATERIALS AND METHODS |
Cell culture and growth arrest.
LU cells (3)
were propagated in Eagle's minimum essential medium containing 10%
fetal bovine serum (FBS) and penicillin (100 U/ml)-streptomycin (100 µg/ml) in a 5% CO2 in air atmosphere. The cells were
density arrested as described previously in detail (19).
Virus stocks and productive infection.
The AD169 strain of
HCMV was propagated in LU cells as previously described in detail
(6). The infectivities of virus stocks, determined by
plaque assay (3), typically were between 8.0 × 106 and 4.0 × 107 PFU/ml. LU cells were
infected with HCMV at a multiplicity of 5 PFU/cell to provide a uniform
infection as described in detail by Bresnahan et al. (19).
Virus stocks and cell cultures were routinely examined for mycoplasma
and were free from detectable contamination.
RNA isolation.
RNA was extracted using Tri Reagent
(Molecular Research Center, Inc., Cincinnati, Ohio), which contains
phenol and guanidine thiocyanate, according to the manufacturer's
protocol (25).
Preparation of probes.
A 32P-labeled DNA probe
was prepared from plasmid pC-waf1-S (generously provided by B. Vogelstein [33]), which harbors a p21cip1
insert. A probe derived from plasmid p5B (16), which
contains the cDNA for 18S rRNA, was used to ensure uniform loading of
gels. Plasmids were introduced into competent Escherichia
coli DH5
cells and amplified. DNA fragments comprising
p21cip1 and 18S cDNA were excised from isolated plasmid DNA
by using the the restriction endonucleases NotI and
BamHI-EcoRI, respectively. The probes were
labeled using the Megaprime DNA Labelling System (Amersham Pharmacia
Biotech, Piscataway, N.J.).
Electrophoresis and Northern hybridization.
Northern
hybridization was performed as described previously (17).
Total cellular RNA (20 µg/lane) was evaluated under denaturing conditions in formaldehyde-agarose gels, containing 1% agarose, 20 mM
3-(N-morpholino) propanesulfonic acid, 1 mM EDTA, 8 mM
sodium acetate, and 2.2 M formaldehyde. After separation, the RNA was transferred to MSI nylon membranes (Micron Separations, Inc., Westborough, Mass.) for 18 h. The RNA was prehybridized in
Rapid-Hyb buffer (Amersham Life Science, Arlington Heights, Ill.)
containing denatured salmon sperm DNA (100 µg/ml) at 65°C for
1 h. 32P-labeled p21cip1 or 18S probe was
added and hybridized for 2 h at 65°C. Membranes were washed
twice with 2× SSPE (1× SSPE is 0.18 M NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7])-0.1%
sodium dodecyl sulfate (SDS) for 15 min at 65°C, once with 1×
SSPE-0.1% SDS at 42°C, and twice with 0.1× SSPE-0.1% SDS at
42°C. The probe remaining on the filter was detected by
autoradiography (Kodak [Rochester, N.Y.] X-Omat film for 1 to 16 h at
80°C).
Western blots.
Polyclonal and monoclonal antibodies for
p21cip1 were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, Calif.). Antibodies against m-calpain, µ-calpain, and
calpastatin were generously provided by R. L. Mellgren
(88). Cells were harvested as we described previously
(19) by dislodging the cells with a cell lifter in
phosphate-buffered saline (PBS). The cells were collected by
sedimentation and lysed in NP-40 lysis buffer (50 mM Tris-HCl [pH
7.4] containing 150 mM NaCl and 0.5% NP-40, with 1 mM dithiothreitol [DTT], 1 mM NaVO3, 50 mM NaF, and protease inhibitors [1
mM phenylmethylsulfonyl fluoride {PMSF}, 25 µg of trypsin
inhibitor/ml, 25 µg of aprotinin/ml, 1 mM benzamide, and 25 µg of
pepstatin A/ml] added just before use). Cellular debris was removed by
sedimentation, and the supernatant fluids were reserved. The protein
concentration was determined by the bicinchoninic acid protein assay
(Pierce, Rockford, Ill.). Whole-cell extracts (40 µg/lane) were
fractionated by SDS-polyacrylamide gel electrophoresis (PAGE), and the
polypeptides were transferred to nitrocellulose membranes (Bio-Rad
Laboratories, Hercules, Calif.) as described previously
(19). Antigen-antibody reactions were detected by the
enhanced chemiluminescence assay (Amersham Pharmacia Biotech) as
recommended by the manufacturer.
Measurement of intracellular calpain activity.
Calpain
activity was measured using the cell-permeant fluorogenic calpain
substrate
tert-butoxycarbonyl-L- leucyl-L-methionineamide-7-amino-4-chloromethylcoumarin (Boc-Leu-Met-CMAC; Molecular Probes, Eugene, Oreg.). HCMV-
or mock-infected cells were loaded with Boc-Leu-Met-CMAC (10 µM) for
15 min at selected times after infection. Subsequently, the cells were
dissociated by trypsinization and resuspended in PBS. After entering
cells, Boc-Leu-Met-CMAC is conjugated to thiols, particularly
glutathione, becoming impermeant for the plasmalemma. Cleavage of
thiol-conjugated Boc-Leu-Met-CMAC by calpain releases thiol-conjugated
7-amino-4-methylcoumarin (AMC), unquenching the fluorescence. Thus,
when cleavage is the rate-limiting step, the observed increase in
fluorescence is proportional to the activity of calpain
(67). Fluorescence intensities of Boc-Leu-Met-CMAC-loaded cells were measured with a SLM 4800S spectrofluorometer. The relative fluorescence intensities were determined by measuring the fluorescence emission values at intervals from 390 to 550 nm, with excitation set at
380 nm. The fluorescence signal was calculated by integrating the area
under the peak at 460 nm. The time interval for loading the cells with
Boc-Leu-Met-CMAC, harvesting the loaded cells, and measurement of
fluorescence was constant for all samples.
Zymography.
Casein zymography was performed by the method of
Zhao et al. (90). Cells were removed from culture dishes
with a cell scraper into cold PBS, collected by sedimentation, and
homogenized in freshly made homogenization buffer [20 mM Tris-HCl (pH
7.4) containing 5 mM EDTA, 5 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 10 µg of
4-(2-aminoethyl)benzenesulfonly fluoride (AEBSF)/ml, 5 µg of
leupeptin/ml and 10 µg of pepstatin A/ml] at 4°C. Cellular debris
was removed by sedimentation, and the supernatant fluids were
collected, quick-frozen with liquid nitrogen, and maintained at
80°C until needed.
For electrophoretic separation of the target proteins, 100 µg of
protein from each sample was mixed with the appropriate amount of 5×
sample buffer (pH 6.8), containing 150 mM Tris-HCl, 20% glycerol, 2 mM
2-mercaptoethanol, and 0.004% bromophenol blue, to obtain a 1× sample
buffer concentration. The samples were then fractionated in
polyacrylamide gels. The separating gel contained 2% casein (wt/vol;
sodium salt) copolymerized with 12% acrylamide, 0.32% (wt/vol)
bisacrylamide, 375 mM Tris-HCl (pH 8.8), 0.04% ammonium
persulfate, and 0.028% (vol/vol)
N,N,N',N'-tetramethylethylenediamine (TEMED). The
stacking gel contained 4% acrylamide, 0.11% (wt/vol) bisacrylamide,
380 mM Tris-HCl (pH 6.8), 0.04% ammonium persulfate, and 0.028%
(vol/vol) TEMED, without casein. The electrophoresis buffer contained
25 mM Tris base, 192 mM glycine, 1 mM EDTA, and 1 mM DTT (pH 8.3).
After electrophoresis, the gel was removed and incubated in incubation
buffer for 60 min at room temperature with slow agitation and with two
changes of buffer. The incubation buffer contained 20 mM Tris-HCl, 10 mM DTT, 3 mM CaCl2 (pH 7.5 for µ-calpain; pH 7.3 for
m-calpain). The gel was incubated for an additional 20 to 24 h and
then stained with Coomassie brilliant blue.
Cleavage of p21cip1 by calpain.
Recombinant
p21cip1 was a gift from J. Wade Harper (41) or
Hengming Ke (53). We also prepared the recombinant
p21cip1 by using the expression plasmid pET-p21, provided
by J. Wade Harper (41), according to the published method
(32). To evaluate the effect of calpains on
p21cip1, 400 ng of purified recombinant p21cip1
was incubated with 0.004 U of either pure µ-calpain or m-calpain at
30°C for 30 min in 40 µl of cleavage buffer (25 mM Tris-HCl [pH
7.5] with 100 mM NaCl, 3 mM DTT, and 5 mM CaCl2)
(50). EDTA was added to 10 mM to stop the reaction. An
equal volume of 2× SDS-PAGE gel-loading buffer (19) was
mixed with the digestion mixture, and the mixture was immediately
boiled for 5 min. The digestion products were evaluated by Western blot
analysis and SDS-PAGE. Antibody preparations used for the detection of
p21cip1 (SC-397 and SC-6246) were obtained from Santa Cruz Biotechnology.
Chemicals.
The calpain inhibitors E64d
[trans-epoxysuccinyl-L-leucylamido
(4-guanidino)-butane] and Z-Leu-Leu-H
(carbobenzoxy-L-leucyl-L-leucinal) were
purchased from Peptides International, Inc. (Louisville, Ky.). Calpain
II (m-calpain), AEBSF, casein, penicillin, streptomycin, diethyl
pyrocarbonate, Tris, NaCl, NaVO3, NaF, PMSF, DTT, trypsin inhibitor, aprotinin, benzamide, and pepstatin A were purchased from
Sigma (St. Louis, Mo.). Calpain I (µ-calpain) and NP-40 were obtained
from Calbiochem (San Diego, Calif.). Boc-Leu-Met-CMAC and CMAC were
purchased from Molecular Probes.
Image processing.
All experiments were repeated at least
twice, and either data from a representative experiment or means of
data from two or more experiments were selected for presentation.
Chemiluminescent samples were exposed for intervals that ensured a
linear response, as determined by standardization. All radiographic
films were analyzed using an AlphaImager 2000 documentation and
analysis system (Alpha Innotech Corp.) and the manufacturer's software (AlphaImager 2000, version 3.x). The images were quantified and recorded as tagged image format files, which were then used to prepare
the graphic images presented in this report.
 |
RESULTS |
p21cip1 RNA and protein levels in HCMV-infected LU
cells.
Previous studies from our laboratory demonstrated that HCMV
infection resulted in a substantial decrease in the abundance of
p21cip1 protein in LU cells (19). To
investigate the mechanism responsible for this drop,
p21cip1 transcript levels were measured by Northern blot
analysis in density-arrested LU cells following stimulation with 10%
FBS, HCMV (5 PFU/cell) infection, or mock infection. The results of a
representative experiment are shown in Fig.
1A. In density-arrested cells, FBS treatment or mock infection had little effect on
p21cip1 RNA levels. Following HCMV infection of
density-arrested LU cells, p21cip1 RNA levels increased
briefly at 3 h postinfection (p.i.) and then decreased over the
next 21 h p.i., whereupon they began to recover, reaching 60% of
their preinfection level at 96 h p.i. (determined by densitometry
[Fig. 1B]). Western blot analysis (Fig. 1C) demonstrated that
p21cip1 protein abundance was not correlated with the
observed changes in RNA levels after 24 h p.i. After an early
increase at 3 h p.i., p21cip1 protein levels fell
dramatically from 3 to 24 h p.i., asymptotically approaching the
limits of detection from 48 to 96 h p.i. (Fig. 1D). These findings
provide clear evidence of a disparity between p21cip1 RNA
and protein levels in the HCMV-infected cells after 24 h p.i.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Northern blot analysis of the effect of HCMV
infection (HCMV), serum growth factors (Serum), or mock infection
(Mock) on p21cip1 RNA transcripts in density-arrested LU
cells. The density-arrested cells were infected with HCMV at a
multiplicity of 5 PFU/cell, exposed to fresh FBS (10%), or mock
infected. RNA was isolated at the times indicated, and 20 µg of RNA
from each lysate was applied to the gel. 18s rRNA (18S) was used as a
loading standard. (B) Results of the representative experiment
illustrated in panel A and of two additional independent experiments,
evaluated by densitometric analysis and plotted as the abundance
relative to the mock-infected control at 0 h p.i. with standard
deviation shown ( , p21cip1 RNA, HCMV-infected cells;
, p21cip1 RNA, mock-infected cells). (C) Western blot
analysis of the abundance of p21cip1 after HCMV infection
or mock infection. Parallel cultures of density-arrested LU cells were
treated as in the legend to panel A. Whole-cell lysates were prepared
at the indicated intervals, and 40 µg of protein from each was
resolved by SDS-PAGE. The proteins were transferred to nitrocellulose
membrane and probed with antibodies against p21cip1. The
results of a representative experiment are illustrated. (D) The results
of the experiment illustrated in panel C and two additional
experiments, evaluated by densitometric analysis and plotted as the
abundance relative to the mock-infected control at 0 h p.i. with
standard deviation shown ( , p21cip1 protein,
HCMV-infected cells; , p21cip1 protein, mock-infected
cells).
|
|
Differential effects of an inhibitor of the ubiquitin-proteasome
proteolytic pathway on p21cip1 degradation during HCMV
infection and mock infection.
Since the ubiquitin-proteasome
pathway is reported to be responsible for degrading many of the cell
cycle regulatory proteins, we investigated whether or not the decrease
of p21cip1 in HCMV-infected cells was due to a
proteasome-mediated mechanism. HCMV (5 PFU/cell)-infected and
mock-infected LU cells were treated with MG132, an inhibitor of
proteasome-mediated proteolysis (56, 69), at 1 h
p.i., and p21cip1 abundance was evaluated at 24 h p.i.
The results of a representative experiment are shown in Fig.
2A. By 24 h p.i.,
p21cip1 levels were substantially lower in HCMV-infected LU
cells (Fig. 2A) than in the control (mock-infected cells). MG132
stabilized p21cip1 in mock-infected, density-arrested LU
cells but had only a limited effect on stabilization of
p21cip1 in HCMV-infected cells (Fig. 2). Mock-infected,
density-arrested LU cells treated with MG132 (0 to 10 µM)
demonstrated a concentration-dependent increase in the abundance of
p21cip1. A greater than fivefold increase in
p21cip1 abundance relative to either the dimethyl sulfoxide
(DMSO) control (lane 2) or cells in the absence of any chemical (lane
1) was observed at concentrations of 5 and 10 µM (Fig. 2). In
HCMV-infected cells, smaller increases in p21cip1 abundance
were observed at MG132 concentrations from 2.5 to 10 µM, reaching a
maximum 2.5-fold increase at 10 µM. That the p21cip1
abundance was less responsive to protection by MG132 in HCMV-infected cells than in mock-infected cells is demonstrated by the significant difference (P < 0.01) in the slopes (determined by
linear regression analysis) of the concentration effect of MG132 in
HCMV-infected (0.800, P < 0.01) and mock-infected
(1.964, P < 0.01) LU cells. These findings suggested
that some additional MG132-insensitive pathway(s) may be involved in
the proteolysis of p21cip1 in HCMV-infected cells. As the
unidentified mechanism(s) seemed to be quantitatively more important in
p21cip1 proteolysis in HCMV-infected cells than was
proteasome-mediated degradation, we were interested in identifying the
proteolytic mechanism(s) stimulated by HCMV infection.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of MG132, an inhibitor of proteasome activity, on
p21cip1 abundance in HCMV- or mock-infected,
density-arrested LU cells. (A) Results of a representative experiment
in which density-arrested LU cells were infected with HCMV (5 PFU/cell)
or mock infected and then exposed to the indicated concentrations of
MG132 beginning at 24 h p.i. Cell lysates were prepared at 30 h p.i. and 40 µg of protein from each lysate was resolved by
SDS-PAGE. The proteins were transferred to nitrocellulose and probed
with antibodies against p21cip1. Control, cells cultured in
the absence of MG132 or its solvent, DMSO; 0, DMSO control, consisting
of cells treated with the same concentration of DMSO (0.1%) present in
the cultural fluids containing the highest concentration of MG132 (10 µM). (B) Change in abundance of p21cip1 after MG132
treatment, determined by densitometry of the results illustrated in
panel A. The results for mock-infected cells (open bars) were
calculated relative to the p21cip1 abundance in untreated
mock-infected cells; the results for HCMV-infected cells (closed bars)
were determined relative to the p21cip1 abundance in
untreated HCMV-infected cells.
|
|
The calpain inhibitors E64d and Z-Leu-Leu-H protect
p21cip1 from degradation during HCMV infection.
HCMV
infection induces substantial increases in intracellular free
Ca2+ (58) and in phospholipid degradation
(1, 2, 81), raising the possibility that
Ca2+-activated neutral proteases (calpains) might be
activated by HCMV infection and participate in the proteolysis of
p21cip1. Previous work has demonstrated that calpains are
able to cleave cell cycle regulatory proteins, such as cyclin D1,
cellular oncogene products (e.g., c-Mos, c-Jun, and c-Fos), and p53
(43, 59; for reviews, see references 21 and
28). The possibility that calpain-mediated proteolysis was
involved in the degradation of p21cip1 in HCMV-infected
cells was investigated first by examining the effect of the
cell-permeable calpain inhibitors E64d (79) and Z-Leu-Leu-H (69) on p21cip1 levels following
HCMV infection.
In initial experiments, we measured the effect of E64d (100 µM) on
p21
cip1 levels by Western blot analysis beginning at
48 h p.i., when
p21
cip1 was near its lowest level
(Fig.
1) in HCMV-infected (5 PFU/cell),
density-arrested LU cells. The
abundance of p21
cip1 was determined at selected intervals
for 24 h following treatment
with E64d. The results of a
representative experiment are shown
in Fig.
3. As noted previously, a substantial
decrease in p21
cip1 levels was observed at 48 h p.i.
in HCMV-infected cells just
prior to treatment with E64d (Fig.
3,
compare lane 1 [lysate of
mock-infected cells prepared at 0 h
p.i.] to lane 2 [lysate of
HCMV-infected cells in the absence of E64d
prepared at 48 h p.i.]).
Except at 3 h after treatment with
E64d, when there was about
a 1.5-fold increase in p21
cip1
in the presence of E64d, the calpain inhibitor had little, if
any,
effect on the abundance of p21
cip1 in mock-infected,
density-arrested LU cells. In contrast, in
HCMV-infected cells in the
presence of E64d, a substantial accumulation
of p21
cip1 was
observed, with a fourfold increase in the abundance of
p21
cip1 in HCMV-infected cells observed after 12 h of
E64d treatment.
In the absence of E64d, levels of p21
cip1
in HCMV-infected cells remained at a constant low level. The
maximum
level of p21
cip1 in the E64d-treated cells under these
conditions was about 84%
of that observed at 0 h. These data
suggested that an E64d-sensitive
proteolytic pathway was induced in
HCMV-infected cells and was
largely responsible for a substantial
decrease in the abundance
of p21
cip1.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Cumulative effect of the calpain inhibitor E64d (100 µM) on p21cip1 protein levels in HCMV- or mock-infected,
density-arrested LU cells. (A) LU cells arrested by contact inhibition
as described in Materials and Methods were infected with HCMV (5 PFU/cell) or mock infected and then exposed to E64d beginning at
48 h p.i. At the times indicated, whole-cell lysates were
prepared, and 40 µg of protein from each lysate was analyzed by
SDS-PAGE. The proteins were transferred to nitrocellulose and probed
with antibodies against p21cip1. The results of a
representative experiment are shown. Hours PT (posttreatment) indicates
the duration of E64d exposure. Hours PI indicates the time of harvest
after infection. The exposure time for blots of lysates from
HCMV-infected cells was about three times longer than that required for
blots of lysates from mock-infected cells. Accordingly, to permit a
quantitative comparison between the p21cip1 abundance at
0 h p.i. and at later times, lane 1 for the HCMV-infected cell
lysates was loaded with a lysate from mock-infected cells not treated
with E64d. (B) Accumulation of p21cip1 after E64d
treatment, determined by densitometry of the data illustrated in panel
A and from two additional experiments. The results for
p21cip1 abundance in HCMV- and mock-infected cells with
standard deviation shown are plotted relative to the
p21cip1 abundance at 0 h in the absence of E64d in
HCMV- and mock-infected cells, respectively ( , mock-infected cells;
, mock-infected cells treated with E64d; , HCMV-infected cells;
, HCMV-infected cells treated with E64d).
|
|
The concentration effect of E64d on p21
cip1 abundance was
examined in HCMV (5 PFU/cell)- and mock-infected, density-arrested LU
cells by addition of selected concentrations of E64d at 48 h p.i.
Whole-cell extracts were prepared 6 h later and evaluated by
Western
blot analysis. The results of a representative experiment are
shown in Fig.
4. Since E64d had little,
if any, effect on p21
cip1 levels in mock-infected cells
even at a concentration of 100
µM, as demonstrated in Fig.
3, the
data for mock-infected cells
are not illustrated in Fig.
4. In
HCMV-infected cells, protection
of p21
cip1 was observed at
all concentrations evaluated (6.25 to 100 µM),
while the quantitative
effect was directly dependent on the concentration
of E64d. Cells
treated with the highest concentration of E64d
(100 µM) demonstrated
about 85% of the p21
cip1 abundance measured in
mock-infected cells over the same time
period (Fig.
4B, compare the
first and last columns).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of E64d concentration on p21cip1
abundance in HCMV-infected cells. (A) LU cells were density arrested as
described in Materials and Methods, HCMV infected (5 PFU/cell) or mock
infected, and at 48 h p.i. treated with the indicated
concentrations of E64d. Whole-cell lysates were prepared 6 h
later, and 40 µg of protein from each lysate was resolved by
SDS-PAGE. The proteins were transferred to nitrocellulose and probed
with antibodies to p21cip1. The results from a
representative experiment are shown. Mock, mock-infected cells in the
absence of drug; Control, untreated HCMV-infected cells; 0, DMSO
control, consisting of HCMV-infected cells treated with the same
concentration of DMSO (0.1%) contained in the highest concentration of
E64d. (B) Densitometric analysis of the results shown in panel A.
|
|
Protection of p21
cip1 by Z-Leu-Leu-H was evaluated by the
same approach as described above. Z-Leu-Leu-H also protected
p21
cip1 in a concentration-dependent manner in HCMV (5 PFU/cell)-infected,
density-arrested LU cells, with some protection
provided by all
concentrations of Z-Leu-Leu-H evaluated. The results of
a representative
experiment are shown in Fig.
5. The levels of protection provided
by
Z-Leu-Leu-H were similar to those observed with E64d (Fig.
4). A
concentration of 100 µM of Z-Leu-Leu-H resulted in detection
of about
72% of the mock-infected levels of p21
cip1 (Fig.
5B,
compare the first and last columns), compared to 85%
for cells treated
with E64d. Z-Leu-Leu-H had little, if any, effect
on the abundance of
p21
cip1 in mock-infected cells (data not shown).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of Z-Leu-Leu-H concentration on
p21cip1 abundance in HCMV-infected cells. (A) LU cells were
density arrested as described in Materials and Methods, infected with
HCMV (5 PFU/cell) or mock infected, and at 48 h p.i. treated with
selected concentrations of Z-Leu-Leu-H. Whole-cell lysates were
prepared 6 h later, and 40 µg of protein from each lysate was
resolved by SDS-PAGE. The proteins were transferred to nitrocellulose
and probed with antibodies to p21cip1. The results
illustrated are those from a representative experiment. Mock, Control,
and 0 are defined in the legend to Fig. 4. (B) Densitometric analysis
of the results illustrated in panel A.
|
|
Sensitivity of p21cip1 degradation to inhibition by
E64d during the HCMV replication cycle.
To determine the effect of
E64d (100 µM) on p21cip1 levels throughout the time
course of HCMV infection, density-arrested LU cell cultures were either
infected with HCMV (5 PFU/cell) or mock infected and treated with E64d
up to 12 h before harvest. For cells harvested at 12 h p.i.
or before, the cells were treated with E64d from 1 h p.i. to the
time of harvest (Fig. 6). E64d had little
effect on p21cip1 levels in mock-infected cells, as
previously noted (Fig. 3), and therefore the results for mock-infected
cells are not shown. The results for HCMV-infected cells from a
representative experiment are shown in Fig. 6A. In the absence of E64d,
p21cip1 levels in HCMV-infected cells increased at 3 h
and began to drop off by 6 h. By 72 and 96 h p.i.,
p21cip1 was only faintly detectable in the HCMV-infected
cells in the absence of E64d. In the presence of E64d,
p21cip1 levels in HCMV-infected cells were significantly
(P < 0.05) greater (from 3 h to 96 h p.i., except
at 12 and 96 h, when the difference, although greater, was not
significant) than the levels observed in the absence of the calpain
inhibitor (Fig. 6B). As a result of E64d treatment, p21cip1
levels remained at or above the preinfection levels through 9 h
p.i. and within 85% of the preinfection levels through 24 h. After 48 h, p21cip1 levels in E64d-treated,
HCMV-infected cells remained well above the levels in the absence of
the calpain inhibitor, but the p21cip1 abundance dropped
progressively below the preinfection levels. Considered together, these
data suggested that calpain-mediated proteolysis contributed
substantially to the degradation of p21cip1 in
HCMV-infected cells from 3 h through the late phase of HCMV infection.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 6.
Time course for the effect of E64d on
p21cip1 abundance in HCMV-infected, density-arrested cells.
(A) LU cells density arrested as described in Materials and Methods
were infected with HCMV (5 PFU/cell) or mock infected; at the intervals
indicated, beginning 1 h p.i., subsets of the cells were treated
with E64d (100 µM). Whole-cell lysates were prepared at the times
indicated (up to 12 h posttreatment [PT]), and 40 µg of
protein from each lysate was resolved by SDS-PAGE. The proteins were
transferred to nitrocellulose and probed with antibodies to
p21cip1. The results of a representative experiment are
illustrated. (B) Densitometric analysis of the results shown in panel A
and two additional experiments with standard deviation. Open bars,
HCMV-infected cells; diagonally striped bars, HCMV-infected cells
treated with E64d; cross-hatched bars, mock-infected cells.
|
|
Calpain is activated by HCMV infection.
The level of calpain
activity is normally very low in unstimulated cells due to the presence
of the endogenous calpain inhibitor calpastatin (21). The
findings that treatment of HCMV-infected cells with E64d or Z-Leu-Leu-H
led to stabilization and accumulation of p21cip1 suggested
that calpain is activated during HCMV infection. To investigate this
possibility, we used the fluorogenic calpain substrate Boc-Leu-Met-CMAC
to measure calpain activity in density-arrested LU cells
(67). Density-arrested LU cells were infected with HCMV (5 PFU/cell) or mock infected and exposed to Boc-Leu-Met-CMAC (10 µM) 15 min before assay. The cells were harvested (see Materials and Methods),
and the relative fluorescence was determined. The results (Fig.
7A) demonstrated that fluorescence from
the product (AMC) of cleavage of the fluorogenic
substrate fell gradually in mock-infected cells during the 48-h course
of these experiments. HCMV infection, however, induced a substantial
increase in calpain activity. An increase in AMC fluorescence was
observed by 6 h p.i. in HCMV-infected cells. After 24 h, the
AMC fluorescence in HCMV-infected cells increased to a value about
2.5-fold greater than that observed in mock-infected cells. The
relative fluorescence observed in the HCMV-infected cells increased
further by 48 h p.i., when it was about eightfold greater than the
fluorescence in mock-infected cells. The increases in calpain activity
from 24 and 48 h were significant (P < 0.05).
These data closely reflect the time course for the changes in the
abundance of p21cip1 following HCMV infection in our
earlier work (19) and in this study. In these studies, a
decrease in p21cip1 levels was first detected at 6 h
p.i., and the abundance of p21cip1 continued to decrease
through 48 h p.i.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 7.
(A) The time course for calpain activity in HCMV
(5 PFU/cell)-infected (solid bars) and mock-infected (open bars)
density-arrested cells. Calpain activity was measured by exposing the
cells to the cell-permeant fluorogenic calpain substrate
Boc-Leu-Met-CMAC (18 µM) for 15 min before the fluorescence intensity
was measured for equal numbers of HCMV- and mock-infected cells, using
an SLM 4800S spectrofluorometer. Excitation was at 380 nm; emission was
at 460 nm. The polarizers were set at 0° and 50°. The data plotted
are the means (± standard deviation) of the findings from three
independent experiments. (B) 1, representative casein zymogram.
Density-arrested LU cells were either infected with HCMV (5 PFU/cell)
or mock infected. The cells were harvested at the times indicated and
processed for zymography as described in Materials and Methods. Since
calpain activity is pH dependent, the gels were incubated in incubation
buffer at either pH 7.5 (optimal for µ-calpain) or pH 7.3 (optimal
for m-calpain). Purified µ- and m-calpain (0.1 U of each) were added
to the sample in lane 1 as a positive control. The upper band in each
lane corresponds to µ-calpain, whereas the lower band corresponds to
m-calpain (89). 2, data for calpain activity based on the
means (± standard deviation) of the intensity of bands at each time
relative to the intensity of the corresponding band at 0 h p.i.
for the zymograms shown above ( , µ-calpain, HCMV-infected cells;
, µ-calpain, mock-infected cells; , m-calpain, HCMV-infected
cells; , m-calpain, mock-infected cells). (C) 1 to 3, abundances of
m-calpain, µ-calpain, and calpastatin in parallel cell cultures as
determined by Western blot analysis (results of a representative
experiment); 4, densitometric analysis of the results shown in panel A
and two additional experiments with standard deviation. Solid symbols
( , m-calpain; , µ-calpain, , calpastatin) and line represent
the means of the results for HCMV-infected cells; open symbols ( ,
m-calpain; , µ-calpain; , calpastatin) and dashed line
represent the results for mock-infected cells. Error bars not shown are
smaller than the symbol.
|
|
Zymography.
Since casein is a well-established target of
calpain-mediated proteolysis (87), we used casein
zymography to verify that calpain was activated in HCMV-infected cells,
to determine which calpain isoenzymes were activated, and to extend the
time course data for calpain activity. Density-arrested LU cells were
infected with HCMV (5 PFU/cell) or mock infected, harvested at times
from 0 to 96 h p.i., and evaluated by casein zymography. The
results of casein zymography to evaluate cellular proteolysis are
illustrated in Fig. 7B. When both of the ubiquitous calpains are
activated, µ-calpain is observed as the upper band, while m-calpain
is observed at a slightly lower position in the nondenaturing gels
(89). The intensity of the bands was related linearly to
the amount of protease activity. Since µ- and m-calpain have slightly
different pH optima, duplicate gels were incubated at pH 7.5 or 7.3 to
evaluate quantitative changes in isoenzyme activity. There was
substantial activity of both ubiquitous calpains at each pH shown when
both calpains were activated. The results for a representative
experiment from this series of experiments (Fig. 7B) demonstrated that
calpain activity gradually decreased in mock-infected cells during the 96-h time course of the experiment. In contrast, HCMV infection induced
an increase in both µ- and m-calpain activities by 6 to 9 h p.i.
(Fig. 7B, part 2). By 24 h, the calpain activity of HCMV-infected cells was about fourfold (µ-calpain) or fivefold (m-calpain) greater than that of mock-infected cells. The enzyme activity continued to
increase and reached its maximum level at 72 h p.i. when it was
about 23-fold (µ-calpain) or 25-fold (m-calpain) greater than that
observed in mock-infected cells. The increases in calpain activities
from 12 to 96 h were significant (P < 0.05)
relative to the preinfection levels. Overall, the changes in calpain
activity measured by casein zymography were remarkably similar to those obtained using the fluorogenic calpain substrate Boc-Leu-Met-CMAC in
intact cells (Fig. 7A) and indicate that HCMV infection was activating
both µ- and m-calpain.
To determine if the increased calpain activity observed in Fig.
7A and
B was a result of increased expression of calpains
or a decrease in the
abundance of calpastatin, the abundance of
these proteins was measured
by Western blot analysis (Fig.
7C)
in cells treated in parallel with
those used to measure calpain
activity (Fig.
7B). HCMV infection had
little, if any, detectable
effect on the abundance of µ-calpain or
calpastatin through 96
h p.i. m-Calpain levels demonstrated a very
slight increase from
6 h to 72 h p.i. over the abundance
observed in mock-infected
cells, and by 96 h, HCMV- and
mock-infected cells demonstrated
similar levels of m-calpain. Given the
very small difference in
the abundance of m-calpain in HCMV- and
mock-infected cells, it
was questionable if this difference had any
significance. Mock
infection had little, if any, effect on the cellular
levels of
µ-calpain, m-calpain, or calpastatin during the time course
of
this series of experiments. Thus, it is unlikely that the
substantial
increase in calpain activity observed in HCMV-infected
cells was
a result of a decrease in calpastatin abundance or of
increases
in the abundance of the ubiquitous
calpains.
Calpain cleaves p21cip1.
Although a number of
proteins are now recognized as targets of calpain-mediated proteolysis
(21), p21cip1 has previously not been included
among them. Accordingly, we were interested in directly testing the
sensitivity of p21cip1 to calpain-mediated proteolysis by
incubating purified recombinant p21cip1, obtained from J. Wade Harper (41) or Hengming Ke (53), with either purified µ-calpain or m-calpain and evaluating the products by
Western blot analysis. We also prepared recombinant p21cip1
by using the expression plasmid pET-p21, provided by J. Wade Harper
(32, 41). Incubation of any of the purified
p21cip1 preparations with purified µ-calpain or m-calpain
resulted in the rapid cleavage of p21cip1, as illustrated
with findings for µ-calpain in Fig. 8A.
Two prominent p21cip1 fragments were observed after
incubation with calpain, consistent with the results from earlier
studies indicating that calpain typically cleaves its target proteins
at a limited number of sites (for a review, see reference
78). Inclusion of E64d in the digestion inhibited the
proteolysis of p21cip1 (Fig. 8A). To investigate if either
of the ubiquitous calpains was removing or modifying the availability
of the epitope that was the target of the anti-p21cip1
antibody used in the Western blot analysis, we incubated
p21cip21 and casein separately with either µ-calpain or
m-calpain and examined the proteolytic products by SDS-PAGE. The
location of polypeptides in the gels was demonstrated by Coomassie
brilliant blue staining. To minimize the loss of small peptides,
electrophoresis of proteins applied to these gels was for a period of
time shorter than used for Western blot analysis (Fig. 8A). A limited
number of cleavage products was observed in the Coomassie blue-stained gels (Fig. 8B) for either casein or p21cip1 incubated with
either of the ubiquitous calpains, as had been observed by Western blot
analysis (Fig. 8A). Thus, p21cip1 appeared to be a target
for proteolysis mediated by either µ- or m-calpain.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 8.
Cleavage of purified recombinant p21cip1 by
purified calpain. (A) p21cip1 (0.4 µg) was incubated with
µ-calpain (0.004 U) for 30 min at 30°C in the presence or absence
of E64d (100 µM), and the resulting products were analyzed by Western
blot analysis as described in Materials and Methods. The data
illustrated are from a representative experiment. (B)
p21cip1 (4 µg) or casein (3 µg) was incubated with 0.04 U of µ-calpain or m-calpain for 30 min at 30°C, and the products of
the digestion were examined by SDS-PAGE and Coomassie brilliant blue
staining. M, Rainbow colored protein molecular weight markers of 97.4, 66, 46, 30, 21.5, and 14.3 kDa (Amersham Life Science). The data
illustrated are from a representative experiment.
|
|
 |
DISCUSSION |
Involvement of p21cip1 in cell cycle progression in
HCMV-infected cells.
Progression through the cell cycle is
regulated by mechanisms that are beginning to be understood (31,
73, 74). Induction of cyclin E-associated kinase activity is
essential for progression through the G1 phase of the cell
cycle (for a review, see reference 49) and preparation of
the cell for DNA synthesis. Data from this laboratory (19)
and others (45) have demonstrated that HCMV infection
substantially increases E kinase activity in arrested cells. In
density-arrested cells, E kinase activity is first substantially increased at 24 h p.i., reaches its maximum level by 72 h,
and is still detectable at 96 h (19), well into the
late phase of HCMV replication.
Several mechanisms have been identified that regulate the activity of E
kinase. For example, an increased cellular abundance
of cyclin E is
associated with activation of E kinase (reference
65 and
references therein). HCMV infection has been shown to
transcriptionally
activate the expression of cyclin E, but the
time course for the
increase in E kinase activity is delayed relative
to the changes in the
cellular abundance of cyclin E (
19). The
cellular levels
of cyclin E protein in density-arrested cells
increase substantially by
12 h p.i., peak by 24 h, and are in
decline by 48 h
(
19). Accordingly, not only does activation
of E kinase
lag behind the increase in cyclin E abundance, but
E kinase remains
activated longer than would be anticipated based
solely on cyclin E
abundance (
19). For example, despite the
decrease in
cyclin E levels at 48 h and continuing reduction thereafter,
E
kinase activity increases remarkably at 48 h p.i., peaks at
72 h, and still remains high at 96 h p.i. The lack of
congruity
in the data for cyclin E abundance and E kinase activity
suggest
that other mechanisms are involved in the regulation of E
kinase
activity in HCMV-infected
cells.
The activity of cyclin E-Cdk2 complexes is also regulated by CKIs,
including p21
cip1. In fact, it has been suggested that
p21
cip1 establishes a threshold in the nucleus (
34,
44,
75,
86),
which must be exceeded if E kinase activity is to
develop from
cyclin E-Cdk2 complexes. Increases in E kinase activity in
HCMV-infected,
density-arrested cells closely parallel a substantial
reduction
in the abundance of p21
cip1 by 24 h p.i.
(
19). Our earlier results suggest that the delay
in
activation of E kinase activity after the increase in cyclin
E
abundance and the persistence of the cyclin E-associated kinase
activity after cyclin E levels are sharply reduced are related
to the
effects of the CKIs p21
cip1 and p27
kip1
(
19). Both p21
cip1 and p27
kip1 are
abundant in quiescent LU cells, contributing to the observed
delay
between increasing cyclin E levels and activation of E kinase
until
cyclin E-Cdk2 complexes exceed the threshold established
by
p21
cip1 and p27
kip1. Later, as cyclin E levels
are falling, E kinase remains active
because HCMV infection stimulates
reduction of both p21
cip1 and p27
kip1,
particularly of p21
cip1 (
19). Thus, the
initial phase of activation of E kinase activity
is associated with a
substantial increase in cylin E levels and
decrease in
p21
cip1 levels, while a substantial and sustained decrease
in p21
cip1 is associated with the persistence of E kinase
activity observed
during HCMV infection (Fig.
1D).
Proteolysis of p21cip1 in mock- and HCMV-infected
cells.
The abundance of each protein in a living cell depends on
the balance between its synthesis and degradation, and therefore intracellular proteolysis is of critical importance in maintaining functional concentrations. In fact, many regulatory proteins are subject to proteolytic degradation, which allows cells to rapidly adjust their concentration. Reduction of p21cip1 levels in
noninfected cells is reported to be mediated by ubiquitination and
proteasome degradation (10, 35, 38, 85). Indeed, in mock-infected LU cells, proteasome degradation was the predominant pathway for p21cip1 proteolysis (Fig. 2). In contrast, the
present results indicate that in HCMV-infected cells, the proteosome is
responsible for little, whereas calpain activity is responsible for
much, of the degradation of p21cip1 observed during the
progression of the virus infection. The early decrease in
p21cip1 abundance appears to be related in part to
decreasing RNA levels (Fig. 1) and in part to increasing
calpain-mediated degradation (Fig. 6). Since the half-life of
p21cip1 is reported to be approximately 2 h
(46), a decrease in RNA levels would predictably result in
lower levels of the protein. When the activity of calpain was inhibited
at these early times (e.g., 9 h p.i.), p21cip1 levels
rose to 158% of the preinfection levels, compared with 83.1% in the
absence of calpain inhibitors (Fig. 6). At 24 h p.i., when a
substantial increase in E kinase activity is first detected, p21cip1 levels are at 23% of their preinfection levels,
but when calpain activity is blocked, p21cip1 levels are at
85% of their preinfection levels. This level of p21cip1 is
similar to the levels observed in absence of calpain inhibition at 9 and 12 h p.i. (83 and 72%, respectively), when E kinase activity is at a very low level (19). Thus, calpain-mediated
mechanisms appear to be responsible for the degradation of a
substantial portion of p21cip1, even at early times in HCMV
replication. At later times (after 48 h), when RNA levels are
relatively constant, calpain-mediated mechanisms are largely
responsible for the continuing decrease in p21cip1
abundance. During this period (48 and 72 h p.i.), inhibition of
calpain-catalyzed proteolysis produced cellular levels of
p21cip1 that were from 77.5 to 36.4% of the preinfection
levels, whereas in the absence of calpain inhibitors, the level of
p21cip1 fell to 10.8 and 6.2%, respectively, of the
preinfection level (Fig. 6). Thus, HCMV-induced activation of calpain
is important at both early and late times in controlling the abundance
of p21cip1 and, accordingly, the activity of the cyclin
E-associated kinase. The calpain effect seems particularly noteworthy
in extending the activation of E kinase well into the late phase of
HCMV replication. Since E kinase activity has been shown to be
necessary for high infectious yields of HCMV (18), it is
tempting to speculate that the sustained calpain activity and
persistent low levels of p21cip1 support durable activation
of E kinase and production of high yields of infectious HCMV. Indeed,
preliminary experiments indicate that a single exposure to Z-Leu-Leu-H
(100 µM) is sufficient to reduce HCMV infectious yields at 96 h
PI by 99.7% (P < 0.05).
Several experimental approaches support the view that calpain activity
and p21
cip1 levels are closely coupled in HCMV-infected
cells. Calpain activity
increases in a temporal pattern that is
consistent with the time
courses for the decrease in
p21
cip1 abundance and the increase in E kinase activity in
HCMV-infected
cells (compare Fig.
7 with Fig.
1; see also reference
19). The
time course for E64d protection of
p21
cip1 (Fig.
3) closely parallels the decrease in
p21
cip1 (Fig.
1) and the increase in calpain activity (Fig.
7). The presence
of inhibitors of calpain activity (E64d, Z-Leu-Leu-H)
protects
up to about 80% of p21
cip1 (Fig.
4 and
5). The
concentration effect of E64d in providing
protection of
p21
cip1 in HCMV-infected LU cells is in the range (6.25 to
100 µM) observed
in earlier studies to protect other targets of
calpain-mediated
proteolysis (
54). In cell-free studies,
purified calpain degrades
purified recombinant p21
cip1
(Fig.
8). Considered together, these results indicate that calpain
activity is largely responsible for the substantial decrease in
p21
cip1 observed during HCMV
infection.
Analysis of PEST sequences in p21cip1.
The
degradation of cellular proteins frequently depends on some structural
feature or consensus sequence. For example, PEST sequences, regions
that are rich in proline (P), glutamic acid (E), serine (S), and
threonine (T), flanked by clusters rich in basic amino acids, are
routinely found in short-lived proteins (66; for a review,
see reference 64). It has been demonstrated that many of
the preferred substrates of calpain possess the PEST motif
(64). Thus, the observation that p21cip1 is
rich in PEST amino acids (33, 41) is of particular
interest. Identification of putative PEST sites from these PEST amino
acids can be facilitated by analysis with the PEST-FIND computer
program (available at either
http://www.icnet.uk/LRITu/projects/pest/index.html or
http://emb1.bcc.univie.ac.at/embnet/tools/bio/PESTfind). Results of
PEST-FIND analysis indicate that p21cip1 contains a PEST
site, located between amino acids 122 and 140 (RSGEQAEGSPGGPGDSQGR), with a PEST-FIND score of +5.11, a
mole fraction of PEDST of 33.47, and a hydrophobicity index of 26.59. Although p21cip1 also contains several other PEST amino
acid-rich sequences, PEST-FIND analysis predicts that these motifs are
poor target PEST sequences, because their PEST-FIND scores are less
than 5 (
13.73,
5.23, +1.57
21.61). PEST sequences are often
conditional proteolytic signals that may be masked in certain
situations but may be activated after binding to ligands or after
posttranslational modification, such as protein phosphorylation
(64). Although statistical analysis has shown a
significant relationship between PEST motifs and rapid protein
degradation (64, 66), the direct role of the sequence in
calpain-mediated proteolysis is still not clear. For some proteins, PEST sequences are not required for calpain-mediated proteolysis (reference 22 and references therein).
Calpain-mediated cleavage of p21cip1.
Our results
show that cleavage of purified recombinant p21cip1 resulted
in two major protein fragments in cell-free experiments (Fig. 8),
consistent with earlier work indicating that cleavage at a limited
number of sites is a characteristic of calpain-mediated proteolysis
(for a review, see reference 78). The absence of these
calpain-mediated p21cip1 fragments in lysates of
HCMV-infected LU cells suggests that these p21cip1
fragments are unstable in living cells. The products of
calpain-mediated p21cip1 cleavage may be subject to further
degradation by the ubiquitin-proteasome or other proteolytic pathways.
This latter possibility is supported by the demonstration that
calpain-dependent cleavage of p53 is necessary for subsequent
ubiquitin-dependent degradation (50).
Calpain activity in HCMV infection.
These results are the
first indication that calpain activity is involved in HCMV infection.
Calpains (EC 3.4.22.17) are a family of cysteine proteases. The two
major calpain isoforms, µ-calpain and m-calpain, which are
ubiquitously distributed in cells, differ in the amount of
Ca2+ required for activation in cell-free assays. They
possess a calmodulin-like Ca2+-binding domain and are
subject to intracellular Ca2+ regulation. Therefore, they
are considered to participate in Ca2+-associated signal
transduction pathways. Calpain activity is associated with the
propagation of Ca2+ signaling (21), in some
instances converting transient signals to more durable and amplified
signals (92). It has been known for some time that HCMV
infection induces a substantial increase in cytosolic Ca2+
activity (58). The timing of the intracellular free
Ca2+ increase in HCMV-infected cells (58) is
consistent with the increase in calpain activity illustrated in Fig. 7.
Activation of calpains is also influenced by phospholipid degradation
(9, 27), and HCMV infection has been previously shown to
stimulate the breakdown of phospholipids. Valyi-Nagy et al.
(81) reported that HCMV infection stimulated the
hydrolysis of phosphatidylinositol 4,5-bisphosphate, yielding increases
in the cellular levels of inositol 1,4,5-trisphosphate and DG.
Increased cellular levels of DG are associated with activation of
arachidonic acid metabolism. Indeed, in HCMV-infected cells,
arachidonic acid metabolism is also stimulated, as revealed by the
release of arachidonic acid and its metabolites (1, 2).
Considered together, these findings indicate that HCMV infection
induces an intracellular environment that is consistent with
stimulation of calpain activity. Further, the data support the
interpretation that the enhanced calpain activity plays a role
in
modulating p21
cip1 abundance, facilitating initiation of
cyclin E-associated kinase
activity, and permitting continued E kinase
activity well into
the late phase of HCMV infection. We have postulated
previously
that the limited progression of the cell cycle observed with
productive
HCMV infection establishes a cellular environment conducive
to
efficient HCMV replication (
5,
19). Activation of the
ubiquitous
calpains and degradation of p21
cip1 appear to be
important components in the cellular changes supporting
limited cell
cycle progression and HCMV
replication.
A role for HCMV IE2-86 in cell cycle regulation has been reported. As
noted previously, IE2-86 participates in activating
transcription from
the cyclin E gene (
17). Other roles for IE2-86
in cell
cycle regulation have also been proposed. IE2-86 interacts
with p53
(
15,
77,
80) and pRb (
37,
40,
47,
63),
which
could help to facilitate HCMV-induced cell cycle traverse.
IE2-86 has
been reported to interact also with p21
cip1
(
76), which could potentially assist in releasing the
p21
cip1-mediated block of cell cycle progression. The
observation that
p21
cip1 abundance substantially declines
during productive HCMV infection
(
19) (Fig.
1) suggests
that IE2-86 binding to p21
cip1 may not be a quantitatively
important mechanism for relief of
the p21
cip1 block in
productively infected cells. It is possible that degradation
of
p21
cip1 may have the peripheral effect of preventing a
substantial reduction
of the effective abundance of IE2-86 and a
corresponding decrease
in its transcriptional effect. It seems somewhat
paradoxical that
IE2-86 has also been reported to block cell cycle
progression
in the S phase (
55,
76), since the published
effects of IE2-86
on cyclin E expression and Cdk activities (through
interaction
with p21
cip1) suggest that IE2-86 should
promote cell cycle progression (
23).
A number of studies
of HCMV infection in permissive arrested cells
have noted that traverse
of the cell cycle during productive infection
is limited to a point at
or near the G
1/S boundary (
19,
30,
52). Other
studies of productive HCMV infection in which arrest
is observed in the
S phase (
45,
55,
76) may be related to
interpreting
uncharacterized DNA synthesis as cellular, when it
may be viral, or the
effects of transfection and expression of
IE2-86 in the absence of the
entire repertoire of HCMV genes.
Indeed, Wiebusch and Hagemeier
(
83) observed that IE2-86 blocked
cell progression in
G
1. Although it is clear that IE2-86 participates
in cell
cycle activation by HCMV, additional work is needed to
characterize its
role and the role of cellular molecules in the
limited cell cycle
progression induced by productive HCMV
infection.
 |
ACKNOWLEDGMENTS |
We thank the following researchers for reagents or constructs
used in this study: B. Vogelstein for the WAF1 plasmid; J. W. Harper for plasmid pET-p21 and for recombinant p21cip1; H. Ke for recombinant p21cip1; R. L. Mellgren for
antibodies with specificity to m-calpain, µ-calpain, or calpastatin;
and B. Xu, X. Liang, and D. Coppenhaver for assistance with
purification of recombinant p21cip1. Thanks also go to M. Rechsteiner, who provided the PEST-FIND computer program. The helpful
advice of T. Wood is also much appreciated. We are grateful to W. R. Fleischmann, Jr., for helpful suggestions in preparing this report.
This work was supported by NIH grants DE11389 (T.A.), NS29261 (A.K.),
and ES10018 (P. Muganda) and by NIEHS Center core grant ES06676.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of Texas Medical Branch,
Galveston, TX 77555-1019. Phone: (409) 772-4902. Fax: (409) 772-3757. E-mail: thomas.albrecht{at}utmb.edu.
 |
REFERENCES |
| 1.
|
AbuBakar, S.,
I. Boldogh, and T. Albrecht.
1990.
Stimulation of [3H] release from [3H]-arachidonic acid prelabeled cells.
Arch. Virol.
113:255-266[CrossRef][Medline].
|
| 2.
|
AbuBakar, S.,
I. Boldogh, and T. Albrecht.
1990.
Human cytomegalovirus stimulates arachidonic acid metabolism through pathways that are affected by inhibitors of phospholipase A2 and protein kinase C.
Biochem. Biophys. Res. Commun.
166:953-959[CrossRef][Medline].
|
| 3.
|
Albrecht, T., and T. H. Weller.
1980.
Heterogeneous morphologic features of plaques induced by five strains of human cytomegalovirus.
Am. J. Clin. Pathol.
73:648-654[Medline].
|
| 4.
|
Albrecht, T.,
I. Boldogh, and M. P. Fons.
1992.
Receptor-initiated activation of cells and their oncogenes by herpes-family viruses.
J. Investig. Dermatol.
98(Suppl.):29S-35S[CrossRef][Medline].
|
| 5.
|
Albrecht, T.,
I. Boldogh,
M. Fons,
C. H. Lee,
S. AbuBakar,
J. M. Russell, and W. W. Au.
1989.
Cell-activation responses to cytomegalovirus infection: relationship to the phasing of CMV replication and to the induction of cellular damage.
Subcell. Biochem.
15:157-202[Medline].
|
| 6.
|
Albrecht, T.,
T. Cavallo,
N. L. Cole, and K. Graves.
1980.
Cytomegalovirus: development and progression of cytopathic effects in human cell culture.
Lab. Investig.
42:1-7[Medline].
|
| 7.
|
Albrecht, T.,
M. Nachtigal,
S. C. St. Jeor, and F. Rapp.
1976.
Induction of cellular DNA synthesis and increased mitotic activity in Syrian hamster embryo cells abortively infected with human cytomegalovirus.
J. Gen. Virol.
30:167-177[Abstract/Free Full Text].
|
| 8.
|
Alford, C. A.,
S. Stagno,
R. F. Pass, and W. J. Britt.
1990.
Congenital and perinatal cytomegalovirus infections.
Rev. Infect. Dis.
12(Suppl.):S745-S753.
|
| 9.
|
Arora, A. S.,
P. de Groen,
Y. Emori, and G. J. Gores.
1996.
A cascade of degradative hydrolase activity contributes to hepatocyte necrosis during anoxia.
Am. J. Physiol.
270:G238-G245[Abstract/Free Full Text].
|
| 10.
|
Blagosklonny, M. V.,
G. S. Wu,
S. Omura, and W. S. el-Deiry.
1996.
Proteasome-dependent regulation of p21WAF1/CIP1 expression.
Biochem. Biophys. Res. Commun.
227:564-569[CrossRef][Medline].
|
| 11.
|
Boldogh, I.,
S. AbuBakar, and T. Albrecht.
1990.
Activation of proto-oncogenes: an immediate early event in human cytomegalovirus infection.
Science
247:561-564[Abstract/Free Full Text].
|
| 12.
|
Boldogh, I.,
S. AbuBakar,
C. Z. Deng, and T. Albrecht.
1991.
Transcriptional activation of cellular oncogenes fos, jun, and myc by human cytomegalovirus.
J. Virol.
65:1568-1571[Abstract/Free Full Text].
|
| 13.
|
Boldogh, I.,
S. AbuBakar,
D. Millinoff,
C. Z. Deng, and T. Albrecht.
1991.
Cellular oncogene activation by human cytomegalovirus: lack of correlation with virus infectivity and IE gene expression.
Arch. Virol.
118:163-177[CrossRef][Medline].
|
| 14.
|
Boldogh, I.,
M. P. Fons, and T. Albrecht.
1993.
Increased activity of DNA-binding proteins in nuclei of human cytomegalovirus-infected MRC-5 cells.
Biochem. Biophys. Res. Commun.
197:1505-1510[CrossRef][Medline].
|
| 15.
|
Bonin, L. R., and J. K. McDougall.
1997.
Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function.
J. Virol.
71:5861-5870[Abstract].
|
| 16.
|
Bowman, L. H.,
B. Rabin, and D. Schlessinger.
1981.
Multiple ribosomal RNA cleavage pathways in mammalian cells.
Nucleic Acids Res.
9:4951-4966[Abstract/Free Full Text].
|
| 17.
|
Bresnahan, W. A.,
T. Albrecht, and E. A. Thompson.
1998.
The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein.
J. Biol. Chem.
273:22075-22082[Abstract/Free Full Text].
|
| 18.
|
Bresnahan, W. A.,
I. Boldogh,
P. Chi,
E. A. Thompson, and T. Albrecht.
1997.
Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication.
Virology
231:239-247[CrossRef][Medline].
|
| 19.
|
Bresnahan, W. A.,
I. Boldogh,
E. A. Thompson, and T. Albrecht.
1996.
Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1.
Virology
224:150-160[CrossRef][Medline].
|
| 20.
|
Bresnahan, W. A.,
E. A. Thompson, and T. Albrecht.
1997.
Human cytomegalovirus infection results in altered Cdk2 subcellular localization.
J. Gen. Virol.
78:1993-1997[Abstract].
|
| 21.
|
Carafoli, E., and M. Molinari.
1998.
Calpain: a protease in search of a function?
Biochem. Biophys. Res. Commun.
247:193-203[CrossRef][Medline].
|
| 22.
|
Carillo, S.,
M. Pariat,
A. M. Steff,
L. Jariel-Encontre,
F. Poulat,
P. Berta, and M. Piechaczyk.
1996.
PEST motifs are not required for rapid calpain-mediated proteolysis of c-fos protein.
Biochem. J.
313:245-251.
|
| 23.
|
Castillo, J. P.,
A. D. Yurochko, and T. F. Kowalik.
2000.
Role of human cytomegalovirus immediate-early proteins in cell growth control.
J. Virol.
74:8028-8037[Abstract/Free Full Text].
|
| 24.
|
Chen, I.-T.,
M. L. Smith,
P. M. O'Connor, and A. J. Fornace, Jr.
1995.
Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21Waf1/Cip1 with PCNA.
Oncogene
11:1931-1937[Medline].
|
| 25.
|
Chomczynski, P.
1993.
A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples.
BioTechniques
15:532-534[Medline].
|
| 26.
|
Ciechanover, A.
1994.
The ubiquitin-proteasome proteolytic pathway.
Cell
79:13-21[CrossRef][Medline].
|
| 27.
|
Coolican, S. A., and D. R. Hathaway.
1984.
Effect of L- -phosphatidylinositol on a vascular smooth muscle Ca2+-dependent protease. Reduction of the Ca2+ requirement for autolysis.
J. Biol. Chem.
259:11627-11630[Abstract/Free Full Text].
|
| 28.
|
Croall, D. E., and G. N. DeMartino.
1991.
Calcium-activated neutral protease (calpain) system: structure, function, and regulation.
Physiol. Rev.
71:813-847[Free Full Text].
|
| 29.
|
de Jong, M. D.,
G. J. Galasso,
B. Gazzard,
P. D. Griffiths,
D. A. Jabs,
E. R. Kern, and S. A. Spector.
1998.
Summary of the 2nd International Symposium on Cytomegalovirus.
Antiviral Res.
39:141-162[CrossRef][Medline].
|
| 30.
|
Dittmer, D., and E. S. Mocarski.
1997.
Human cytomegalovirus infection inhibits G1/S transition.
J. Virol.
71:1629-1634[Abstract].
|
| 31.
|
Draetta, G. F.
1994.
Mammalian G1 cyclins.
Curr. Opin. Cell Biol.
6:842-846[CrossRef][Medline].
|
| 32.
|
Dynlacht, B. D.,
C. Ngwu,
J. Winston,
E. C. Swindell,
S. J. Elledge,
E. Harlow, and J. W. Harper.
1997.
Purification and analysis of CIP/KIP proteins.
Methods Enzymol.
283:230-244[Medline].
|
| 33.
|
El-Deiry, W. S.,
T. Tokino,
V. E. Velculescu,
D. B. Levy,
R. Parsons,
J. M. Trent,
D. Lin,
W. E. Mercer,
K. W. Kinzler, and B. Vogelstein.
1993.
WAF1, a potential mediator of p53 tumor suppression.
Cell
75:817-825[CrossRef][Medline].
|
| 34.
|
Elledge, S. J., and J. W. Harper.
1994.
Cdk inhibitors: on the threshold of checkpoints and development.
Curr. Opin. Cell Biol.
6:847-852[CrossRef][Medline].
|
| 35.
|
Elledge, S. J., and J. W. Harper.
1998.
The role of protein stability in the cell cycle and cancer.
Biochim. Biophys. Acta
1377:M61-M70[Medline].
|
| 36.
|
Flores-Rozas, H.,
Z. Kelman,
F. B. Dean,
Z. Q. Pan,
J. W. Harper,
S. J. Elledge,
M. O'Donnell, and J. Hurwitz.
1994.
Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase holoenzyme.
Proc. Natl. Acad. Sci. USA
91:8655-8659[Abstract/Free Full Text].
|
| 37.
|
Fortunato, E. A.,
M. H. Sommer,
K. Yoder, and D. H. Spector.
1997.
Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other.
J. Virol.
71:8176-8185[Abstract].
|
| 38.
|
Fukuchi, K.,
S. Tomoyasu,
T. Nakamaki,
N. Tsuruoka, and K. Gomi.
1998.
DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells.
Biochim. Biophys. Acta
1404:405-411[Medline].
|
| 39.
|
Gervais, J. L.,
P. Seth, and H. Zhang.
1998.
Cleavage of CDK inhibitor p21Cip1/Waf1 by caspases is an early event during DNA damage-induced apoptosis.
J. Biol. Chem.
273:19207-19212[Abstract/Free Full Text].
|
| 40.
|
Hagemeier, C.,
R. Caswell,
G. Hayhurst,
J. Sinclair, and T. Kouzarides.
1994.
Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.
EMBO J.
13:2897-2903[Medline].
|
| 41.
|
Harper, J. W.,
G. R. Adami,
N. Wei,
K. Keyomarsi, and S. J. Elledge.
1993.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Cell
75:805-816[CrossRef][Medline].
|
| 42.
|
Harper, J. W.,
S. J. Elledge,
K. Keyomarsi,
B. Dynlacht,
L. H. Tsai,
P. Zhang,
S. Dobrowolski,
C. Bai,
L. Connell-Crowley,
E. Swindell,
M. P. Fox, and N. Wei.
1995.
Inhibition of cyclin-dependent kinases by p21.
Mol. Biol. Cell
6:387-400[Abstract].
|
| 43.
|
Hirai, S.,
H. Kawasaki,
M. Yaniv, and K. Suzuki.
1991.
Degradation of transcription factors, c-Jun and c-Fos, by calpain.
FEBS Lett.
287:57-61[CrossRef][Medline].
|
| 44.
|
Hunter, T., and J. Pines.
1994.
Cyclins and cancer II: cyclin D and CDK inhibitors come of age.
Cell
79:573-582[CrossRef][Medline].
|
| 45.
|
Jault, F. M.,
J. M. Jault,
F. Ruchti,
E. A. Fortunato,
C. Clark,
J. Corbeil,
D. D. Richman, and D. H. Spector.
1995.
Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.
J. Virol.
69:6697-6704[Abstract].
|
| 46.
|
Johannesesn, L. E.,
S. L. Knardal, and I. H. Madshus.
1999.
Epidermal growth factor increases the level of cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein.
Biochem. J.
337:599-606.
|
| 47.
|
Johnson, R. A.,
A. D. Yurochko,
E. E. Poma,
L. Zhu, and E. S. Huang.
1999.
Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 protein-protein interaction and the possible functional consequences.
J. Gen. Virol.
80:1293-1303[Abstract].
|
| 48.
|
Kearsey, J. M.,
P. J. Coates,
A. R. Prescott,
E. Warbrick, and P. A. Hall.
1995.
Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1.
Oncogene
11:1675-1683[Medline].
|
| 49.
|
Keyomarsi, K., and T. W. Herliczek.
1997.
The role of cyclin E in cell proliferation, development and cancer.
Prog. Cell Cycle Res.
3:171-191[Medline].
|
| 50.
|
Kubbutat, M. H., and K. H. Vousden.
1997.
Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability.
Mol. Cell. Biol.
17:460-468[Abstract].
|
| 51.
|
Li, R.,
S. Waga,
G. J. Hannon,
D. Beach, and B. Stillman.
1994.
Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair.
Nature
371:534-537[CrossRef][Medline].
|
| 52.
|
Lu, M., and T. Shenk.
1996.
Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S.
J. Virol.
70:8850-8857[Abstract].
|
| 53.
|
Mayrose, D. R.,
M. A. Nichols,
Y. Xiong, and H. Ke.
1996.
Purification and crystallization of cyclin-dependent kinase inhibitor p21.
Protein Sci.
5:1928-1930[Medline].
|
| 54.
|
Mellgren, R. L.
1997.
Evidence for participation of a calpain-like cysteine protease in cell cycle progression through late G1 phase.
Biochem. Biophys. Res. Commun.
236:555-558[CrossRef][Medline].
|
| 55.
|
Murphy, E. A.,
D. N. Streblow,
J. A. Nelson, and M. Stinski.
2000.
The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells.
J. Virol.
74:7198-7118.
|
| 56.
|
Murray, E. J.,
G. V. Bentley,
M. S. Grisanti, and S. S. Murray.
1998.
The ubiquitin-proteasome system and cellular proliferation and regulation in osteoblastic cells.
Exp. Cell Res.
242:460-469[CrossRef][Medline].
|
| 57.
|
Noda, A.,
Y. Ning,
S. F. Venable,
O. M. Pereira-Smith, and J. R. Smith.
1994.
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen.
Exp. Cell Res.
211:90-98[CrossRef][Medline].
|
| 58.
|
Nokta, M.,
D. Eaton,
O. S. Steinsland, and T. Albrecht.
1987.
Ca2+ responses in cytomegalovirus-infected fibroblasts of human origin.
Virology
157:259-267[CrossRef][Medline].
|
| 59.
|
Pahl, H. L., and P. A. Baeuerle.
1996.
Control of gene expression by proteolysis.
Curr. Opin. Cell Biol.
8:340-347[CrossRef][Medline].
|
| 60.
|
Pan, Z. Q.,
J. T. Reardon,
L. Li,
H. Flores-Rozas,
R. Legerski,
A. Sancar, and J. Hurwitz.
1995.
Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21.
J. Biol. Chem.
270:22008-22016[Abstract/Free Full Text].
|
| 61.
|
Perez, J. L.
1997.
Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Microbiologia
13:343-352[Medline].
|
| 62.
|
Podust, V. N.,
L. M. Podust,
F. Goubin,
B. Ducommun, and U. Hubscher.
1995.
Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21.
Biochemistry
34:8869-8875[CrossRef][Medline].
|
| 63.
|
Poma, E. E.,
T. F. Kowalik,
L. Zhu,
J. H. Sinclair, and E. S. Huang.
1996.
The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter.
J. Virol.
70:7867-7877[Abstract].
|
| 64.
|
Rechsteiner, M., and S. W. Rogers.
1996.
PEST sequences and regulation by proteolysis.
Trends Biochem. Sci.
21:267-271[CrossRef][Medline].
|
| 65.
|
Resnitzky, D.,
M. Gossen,
H. Bujard, and S. I. Reed.
1994.
Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system.
Mol. Cell. Biol.
14:1669-1679[Abstract/Free Full Text].
|
| 66.
|
Rogers, S.,
R. Wells, and M. Rechsteiner.
1986.
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis.
Science
234:364-368[Abstract/Free Full Text].
|
| 67.
|
Rosser, B. G.,
S. P. Powers, and G. J. Gores.
1993.
Calpain activity increases in hepatocytes following addition of ATP. Demonstration of a novel fluorescent approach.
J. Biol. Chem.
268:23593-23600[Abstract/Free Full Text].
|
| 68.
|
Rubin, R. H.
1990.
Impact of cytomegalovirus infection on organ transplant recipients.
Rev. Infect. Dis.
12(Suppl.):S754-S766.
|
| 69.
|
Saito, Y.,
S. Tsubuki,
H. Ito, and S. Kawashima.
1990.
The structure-function relationship between peptide aldehyde derivatives on initiation of neurite outgrowth in PC12h cells.
Neurosci. Lett.
120:1-4[CrossRef][Medline].
|
| 70.
|
Santella, L.
1998.
The role of calcium in the cell cycle: facts and hypotheses.
Biochem. Biophys. Res. Commun.
244:317-324[CrossRef][Medline].
|
| 71.
|
Santella, L.,
K. Kyozuka,
L. De Riso, and E. Carafoli.
1998.
Calcium, protease action, and the regulation of the cell cycle.
Cell Calcium
23:123-130[CrossRef][Medline].
|
| 72.
|
Schooley, R. T.
1990.
Cytomegalovirus in the setting of infection with human immunodeficiency virus.
Rev. Infect. Dis.
12(Suppl.):S811-S819.
|
| 73.
|
Sherr, C. J.
1993.
Mammalian G1 cyclins.
Cell
73:1059-1065[Medline].
|
| 74.
|
Sherr, C. J.
1994.
G1 phase progression: cycling on cue.
Cell
79:551-555[CrossRef][Medline].
|
| 75.
|
Sherr, C. J., and J. M. Roberts.
1995.
Inhibitors of mammalian G1 cyclin-dependent kinases.
Genes Dev.
9:1149-1163[Free Full Text].
|
| 76.
|
Sinclair, J.,
J. Baillie,
L. Bryant, and R. Caswell.
2000.
Human cytomegalovirus mediates cell cycle progression through G1 into early S phase in terminally differentiated cells.
J. Gen. Virol.
81:1553-1565[Abstract/Free Full Text].
|
| 77.
|
Speir, E.,
E. S. Huang,
R. Modali,
M. B. Leon,
F. Shawl,
T. Finkel, and S. E. Epstein.
1995.
Interaction of human cytomegalovirus with p53: possible role in coronary restenosis.
Scand. J. Infect. Dis. Suppl.
99:78-81[Medline].
|
| 78.
|
Suzuki, K., and H. Sorimachi.
1998.
A novel aspect of calpain activation.
FEBS Lett.
433:1-4[CrossRef][Medline].
|
| 79.
|
Tamai, M.,
K. Matsumoto,
S. Omura,
L. Koyama,
Y. Ozawa, and K. Hanada.
1986.
In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64.
J. Pharmacobiodyn.
9:672-677[Medline].
|
| 80.
|
Tsai, H. L.,
G. H. Kou,
S. C. Chen,
C. W. Wu, and Y. S. Lin.
1996.
Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53.
J. Biol. Chem.
271:3534-3540[Abstract/Free Full Text].
|
| 81.
|
Valyi-Nagy, T.,
Z. Bandi,
I. Boldogh, and T. Albrecht.
1988.
Hydrolysis of inositol lipids: an early signal of human cytomegalovirus infection.
Arch. Virol.
101:199-207[CrossRef][Medline].
|
| 82.
|
Waga, S.,
G. J. Hannon,
D. Beach, and B. Stillman.
1994.
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.
Nature
369:574-578[CrossRef][Medline].
|
| 83.
|
Wiebusch, L., and C. Hagemeier.
1999.
Human cytomegalovirus 86-kilodalton IE2 protein blocks cell cycle progression in G1.
J. Virol.
73:9274-9283[Abstract/Free Full Text].
|
| 84.
|
Xiong, Y.,
G. J. Hannon,
H. Zhang,
D. Casso,
R. Kobayashi, and D. Beach.
1993.
p21 is a universal inhibitor of cyclin kinases.
Nature
366:701-704[CrossRef][Medline].
|
| 85.
|
Yu, Z. K.,
J. L. Gervais, and H. Zhang.
1998.
Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21CIP1/WAF1 and cyclin D proteins.
Proc. Natl. Acad. Sci. USA
95:11324-11329[Abstract/Free Full Text].
|
| 86.
|
Zhang, H.,
G. J. Hannon, and D. Beach.
1994.
p21-containing cyclin kinases exist in both active and inactive states.
Genes Dev.
8:1750-1758[Abstract/Free Full Text].
|
| 87.
|
Zhang, W., and R. L. Mellgren.
1996.
Calpain subunits remain associated during catalysis.
Biochem. Biophys. Res. Commun.
227:891-896[Medline].
|
| 88.
|
Zhang, W.,
R. D. Lane, and R. L. Mellgren.
1996.
The major calpain isozymes are long-lived proteins. Design of an antisense strategy for calpain depletion in cultured cells.
J. Biol. Chem.
271:18825-18830[Abstract/Free Full Text].
|
| 89.
|
Zhao, X.,
J. K. Newcomb,
R. M. Posmantur,
K. K. Wang,
B. R. Pike, and R. L. Hayes.
1998.
pH dependency of mu-calpain and m-calpain activity assayed by casein zymography following traumatic brain injury in the rat.
Neurosci. Lett.
247:53-57[CrossRef][Medline].
|
| 90.
|
Zhao, X.,
R. Posmantur,
A. Kampfl,
S. J. Liu,
K. K. Wang,
J. K. Newcombm,
B. R. Pike,
G. L. Clifton, and R. L. Hayes.
1998.
Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: a casein zymography study.
J. Cereb. Blood Flow Metab.
18:161-167[CrossRef][Medline].
|
| 91.
|
Zhu, H.,
J. P. Cong,
G. Mamtora,
T. Gingeras, and T. Shenk.
1998.
Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays.
Proc. Natl. Acad. Sci. USA
95:14470-14475[Abstract/Free Full Text].
|
| 92.
|
Zimmerman, U. J.,
M. Wang,
J. B. Nelson,
F. S. Ekwunife, and L. Liu.
1996.
Secretagogue-induced proteolysis of cAMP-dependent protein kinase in intact rat alveolar epithelial type II cells.
Biochim. Biophys. Acta
1311:117-123[Medline].
|
Journal of Virology, April 2001, p. 3613-3625, Vol. 75, No. 8
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.8.3613-3625.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hwang, E.-S., Zhang, Z., Cai, H., Huang, D. Y., Huong, S.-M., Cha, C.-Y., Huang, E.-S.
(2009). Human Cytomegalovirus IE1-72 Protein Interacts with p53 and Inhibits p53-Dependent Transactivation by a Mechanism Different from That of IE2-86 Protein. J. Virol.
83: 12388-12398
[Abstract]
[Full Text]
-
Chen, Z., Knutson, E., Wang, S., Martinez, L. A., Albrecht, T.
(2007). Stabilization of p53 in Human Cytomegalovirus-initiated Cells Is Associated with Sequestration of HDM2 and Decreased p53 Ubiquitination. J. Biol. Chem.
282: 29284-29295
[Abstract]
[Full Text]
-
Shlapobersky, M., Sanders, R., Clark, C., Spector, D. H.
(2006). Repression of HMGA2 Gene Expression by Human Cytomegalovirus Involves the IE2 86-Kilodalton Protein and Is Necessary for Efficient Viral Replication and Inhibition of Cyclin A Transcription.. J. Virol.
80: 9951-9961
[Abstract]
[Full Text]
-
Sanchez, V., Spector, D. H.
(2006). Cyclin-Dependent Kinase Activity Is Required for Efficient Expression and Posttranslational Modification of Human Cytomegalovirus Proteins and for Production of Extracellular Particles.. J. Virol.
80: 5886-5896
[Abstract]
[Full Text]
-
Zhang, Z., Evers, D. L., McCarville, J. F., Dantonel, J.-C., Huong, S.-M., Huang, E.-S.
(2006). Evidence that the Human Cytomegalovirus IE2-86 Protein Binds mdm2 and Facilitates mdm2 Degradation.. J. Virol.
80: 3833-3843
[Abstract]
[Full Text]
-
McCormick, A. L., Meiering, C. D., Smith, G. B., Mocarski, E. S.
(2005). Mitochondrial Cell Death Suppressors Carried by Human and Murine Cytomegalovirus Confer Resistance to Proteasome Inhibitor-Induced Apoptosis. J. Virol.
79: 12205-12217
[Abstract]
[Full Text]
-
Castillo, J. P., Frame, F. M., Rogoff, H. A., Pickering, M. T., Yurochko, A. D., Kowalik, T. F.
(2005). Human Cytomegalovirus IE1-72 Activates Ataxia Telangiectasia Mutated Kinase and a p53/p21-Mediated Growth Arrest Response. J. Virol.
79: 11467-11475
[Abstract]
[Full Text]
-
Song, Y.-J., Stinski, M. F.
(2005). Inhibition of Cell Division by the Human Cytomegalovirus IE86 Protein: Role of the p53 Pathway or Cyclin-Dependent Kinase 1/Cyclin B1. J. Virol.
79: 2597-2603
[Abstract]
[Full Text]
-
Kalamvoki, M., Mavromara, P.
(2004). Calcium-Dependent Calpain Proteases Are Implicated in Processing of the Hepatitis C Virus NS5A Protein. J. Virol.
78: 11865-11878
[Abstract]
[Full Text]
-
Sanchez, V., McElroy, A. K., Yen, J., Tamrakar, S., Clark, C. L., Schwartz, R. A., Spector, D. H.
(2004). Cyclin-Dependent Kinase Activity Is Required at Early Times for Accurate Processing and Accumulation of the Human Cytomegalovirus UL122-123 and UL37 Immediate-Early Transcripts and at Later Times for Virus Production. J. Virol.
78: 11219-11232
[Abstract]
[Full Text]
-
Chen, C.-J., Sugiyama, K., Kubo, H., Huang, C., Makino, S.
(2004). Murine Coronavirus Nonstructural Protein p28 Arrests Cell Cycle in G0/G1 Phase. J. Virol.
78: 10410-10419
[Abstract]
[Full Text]
-
Delmas, C., Aragou, N., Poussard, S., Cottin, P., Darbon, J.-M., Manenti, S.
(2003). MAP Kinase-dependent Degradation of p27Kip1 by Calpains in Choroidal Melanoma Cells. REQUIREMENT OF p27Kip1 NUCLEAR EXPORT. J. Biol. Chem.
278: 12443-12451
[Abstract]
[Full Text]
-
Wiebusch, L., Asmar, J., Uecker, R., Hagemeier, C.
(2003). Human cytomegalovirus immediate-early over protein 2 (IE2)-mediated activation of cyclin E is cell-cycle-independent and forces S-phase entry in IE2-arrested cells. J. Gen. Virol.
84: 51-60
[Abstract]
[Full Text]
-
Noris, E., Zannetti, C., Demurtas, A., Sinclair, J., De Andrea, M., Gariglio, M., Landolfo, S.
(2002). Cell Cycle Arrest by Human Cytomegalovirus 86-kDa IE2 Protein Resembles Premature Senescence. J. Virol.
76: 12135-12148
[Abstract]
[Full Text]